Krebs Biochemicals & Industries Limited
National Stock Exchange of IndiaTotal Valuation
Krebs Biochemicals & Industries Limited carries a market capitalization of 1.26B, placing it among publicly traded companies globally. Its enterprise value stands at 3.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.26B |
| Enterprise Value | 3.10B |
Share Statistics
Krebs Biochemicals & Industries Limited currently has 21.56M shares outstanding.
| Shares Outstanding | 21.56M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.61, and the price-to-book ratio stands at 3.97.
| PE Ratio | N/A |
| PS Ratio | 3.61 |
| PB Ratio | 3.97 |
| P/TBV Ratio | -0.52 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 13.07 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 43.77 |
Financial Position
Krebs Biochemicals & Industries Limited maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -138.15, indicating conservative leverage, while an interest coverage ratio of -1.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.09 |
| Quick Ratio | 0.00 |
| Debt / Equity | -138.15 |
| Debt / EBITDA | -18.94 |
| Interest Coverage | -1.68 |
Financial Efficiency
| Return on Equity (ROE) | -78.54 |
| Return on Assets (ROA) | -10.19 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.07 |
Stock Price Statistics
Krebs Biochemicals & Industries Limited's stock has declined approximately -31.98046% over the past 52 weeks. The 50-day moving average sits at 62.22, while the 200-day moving average is 62.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | -31.98046% |
| 50-Day Moving Average | 62.22 |
| 200-Day Moving Average | 62.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Krebs Biochemicals & Industries Limited generated 237.32M in revenue and converted that into -169.33M in net income, yielding earnings per share of -7.86. EBITDA reached -118.73M, while operating income came in at -118.73M.
| Revenue | 237.32M |
| Gross Profit | 233.41M |
| Operating Income | -118.73M |
| Pretax Income | -169.33M |
| Net Income | -169.33M |
| EBITDA | -118.73M |
| EBIT | -118.73M |
| Earnings Per Share (EPS) | -7.86 |
Balance Sheet
Krebs Biochemicals & Industries Limited holds 3.13M in cash and equivalents against 2.25B in total debt, resulting in a net debt position of 2.25B. Total book value stands at 215.61M, with working capital of -1.03B providing operational flexibility.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | 2.25B |
| Net Debt | 2.25B |
| Equity (Book Value) | 215.61M |
| Book Value Per Share | 10.01 |
| Working Capital | -1.03B |
Margins
Krebs Biochemicals & Industries Limited operates with a gross margin of 98.35, reflecting its pricing power and cost economics. The operating margin of -50.03 and net profit margin of -71.35 provide insight into operational efficiency.
| Gross Margin | 98.35 |
| Operating Margin | -50.03 |
| Pretax Margin | -71.35 |
| Profit Margin | -71.35 |
| EBITDA Margin | -50.03 |
Stock Splits
Krebs Biochemicals & Industries Limited's most recent stock split took place on January 31, 2019 with a 200:207 split ratio.
| Last Split Date | 1/31/2019 |
| Split Ratio | 200:207 |
Scores
Krebs Biochemicals & Industries Limited posts an Altman Z-Score of -0.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.70 |